CLAIMS

1. An antituberculous therapeutic drug combination comprising:
(I) 2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b] oxazole, and
(II) at least one drug selected from anti-HIV drugs.

2. The tuberculous therapeutic drug combination according to claim 1, wherein the at least one selected from the anti-HIV drugs is (a) a reverse transcriptase inhibitor based on a nucleic acid, (b) a reverse transcriptase inhibitor based on a non-nucleic acid or (c) a protease inhibitor.

3. The tuberculous therapeutic drug combination according to claim 1, wherein said anti-HIV drugs are selected from the group consisting of lopinavir, ritonavir and efavirenz.

4. The antituberculous therapeutic drug combination according to claim 1, which is in the form of two preparations obtained by formulating the oxazole compound (I) and drugs (II) separately, for simultaneous administration in the same administration route.

5. The antituberculous therapeutic drug combination according to claim 1, which is in the form of two preparations obtained by formulating the oxazole compound (I) and drugs (II) separately, for administration with time difference in the same administration route.

6. A kit for tuberculosis comprising:
(I) 2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy) piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b] oxazole, and
(II) at least one drug selected from anti-HIV drugs, wherein the at least one selected from the anti-HIV drugs is (a) a reverse transcriptase inhibitor based on a nucleic acid, (b) a reverse transcriptase inhibitor based on a non-nucleic acid or (c) a protease inhibitor.

CLAIMS

1. An antituberculous therapeutic drug comprising:

(I) at least one selected from the group consisting of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compounds represented by general formula (1):



(1)

[wherein R^1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R^2 represents any group of the following general formulas (A)-(G), wherein

the group represented by the general formula (A) is:



(A)

wherein R^3 represents any group of the following (1)-(6):

(1) a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(2) a phenyl C1-6 alkoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may

be substituted on the phenyl ring);

(3)-NR^4R^5 group, wherein R^4 represents a hydrogen atom or C1-6 alkyl group and R^5 represents a phenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(4) a phenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(5) a phenoxy C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring); and

(6) a benzofuryl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the benzofuran ring);

the group represented by the general formula (B) is:



(B)

wherein R^6 represents a phenyl group (at least one group selected from the group consisting of a halogen atom,

an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (C) is:



(C)

wherein R^7 represents a phenyl C2-10 alkenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or a biphenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (D) is:



(D)

wherein R^8 represents a phenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (E) is:



(E)

(wherein R^8 is as described above); and

the group represented by the general formula (F) is:



(F)

(wherein R^6 is as described above),

the group represented by the general formula (G) is:



(G)

(wherein R^8 is as described above)],

optically active forms thereof and pharmacologically acceptable salts thereof, and

(II) at least one drug selected from the group consisting of primary antituberculous drugs, secondary antituberculous drugs, quinolone antibacterial drugs, macrolide antibacterial drugs, sulfa drugs, and anti-HIV drugs.

2. The antituberculous therapeutic drug according to claim 1, wherein the drug of (II) is at least one selected from the group consisting of the primary antituberculous drugs, the secondary antituberculous drugs and the quinolone antibacterial drugs.

3. The antituberculous therapeutic drug

according to claim 2, wherein the drug selected from the primary antituberculous drug is at least one selected from the group consisting of rifamycin and related anti-bacterial drugs, isoniazid, ethambutol, streptomycin, pyrazinamide and salts thereof, and the drug selected from the secondary antituberculous drug is at least one selected from the group consisting of enviomycin, kanamycin, capreomycin, cycloserine, thioacetazone, clofazimine and salts thereof.

4. The antituberculous therapeutic drug according to claim 2, wherein the drug of (II) is at least one selected from the primary antituberculous drugs.

5. The antituberculous therapeutic drug according to claim 4, wherein the at least one selected from the primary antituberculous drugs comprises in combination (i) at least one of rifamycin and related anti-bacterial drugs and (ii) at least one selected from the group consisting of isoniazid, ethambutol, streptomycin, pyrazinamide and salts thereof.

6. The antituberculous therapeutic drug according to claim 5, wherein the at least one selected from the primary antituberculous drugs comprises in combination (i) a least one of rifamycin and related anti-bacterial drugs and (ii) pyrazinamide.

7. The antituberculous therapeutic drug according to claim 4, wherein the at least one selected from the primary antituberculous drugs comprises in

combination

(i) at least one of rifamycin and related anti-bacterial drug(s),

(ii) pyrazinamide, and

(iii) at least one selected from the group consisting of isoniazid, ethambutol and streptomycin.

8. The antituberculous therapeutic drug according to any one of claims 3 to 7, wherein the at least one of rifamycin and related anti-bacterial drugs is at least one selected from the group consisting of rifampicin, rifabutin and rifapentine.

9. The antituberculous therapeutic drug according to claim 8, wherein the a least one of rifamycin and related anti-bacterial drug is rifampicin.

10. The antituberculous therapeutic drug according to claim 1, wherein the drug of (II) is at least one selected from the quinolone antibacterial drugs.

11. The antituberculous therapeutic drug according to claim 10, wherein the at least one selected from the quinolone antibacterial drugs is at least one selected from the group consisting of gatifloxacin, moxifloxacin and hydrates thereof.

12. The antituberculous therapeutic drug according to claim 10, wherein the at least one selected from the drugs of (II) comprises in combination at least one selected from the group

consisting of gatifloxacin, moxifloxacin and hydrates thereof and at least one primary antituberculous drug.

13. The antituberculous therapeutic drug according to claim 12, wherein the at least one selected from the primary antituberculous therapeutic drugs comprises in combination (i) any of rifamycin and related antibacterial drugs and (ii) at least one selected from the group consisting of isoniazid, ethambutol, streptomycin, pyrazinamide and salt thereof.

14. The antituberculous therapeutic drug according to claim 13, wherein the at least one selected from the primary antituberculous therapeutic drugs comprises in combination (i) at least one of rifamycin and related antibacterial drugs and (ii) pyrazinamide.

15. The antituberculous therapeutic drug according to claim 14, wherein the at least one selected from the primary antituberculous drugs comprises in combination

(i) at least one of rifamycin and related antibacterial drugs,

(ii) pyrazinamide, and

(iii) at least one selected from the group consisting of isoniazid, ethambutol and streptomycin.

16. The antituberculous therapeutic drug according to any one of claims 13 to 15, wherein the at least one of rifamycin and related antibacterial drugs

is at least one selected from the group consisting of rifamycin, rifabutin and rifapentine.

17. The antituberculous therapeutic drug according to claim 16, wherein the at least one of rifamycin and related antibacterial drugs is rifampicin.

18. The antituberculous therapeutic drug according to claim 1, wherein the drugs of (II) is at least one selected from the macrolide antibacterial drugs.

19. The antituberculous therapeutic drug according to claim 18, wherein the at least one selected from the macrolide antibacterial drugs is at least one selected from the group consisting of clarithromycin, azithromycin and hydrates thereof.

20. The antituberculous therapeutic drug according to claim 1, wherein the drug of (II) is at least one selected from the sulfa drugs.

21. The antituberculous therapeutic drug according to claim 20, wherein the at least one selected from the sulfa drugs is at least one selected from the group consisting of sulfamethizole, sulfisoxazole, sulfamonomethoxine, sulfadimethoxine, sulfamethizole, salazosulfapyridine, sulfadiazine and salts thereof.

22. The antituberculous therapeutic drug according to claim 1, wherein the drug of (II) is at least one selected from the anti-HIV drugs.

23. The antituberculous therapeutic drug according to claim 22, wherein the at least one selected from the anti-HIV drugs is (a) a reverse transcriptase inhibitor based on a nucleic acid, (b) a reverse transcriptase inhibitor based on a non-nucleic acid or (c) a protease inhibitor.

24. A medicament for dosing at an interval of 48 hours or more, wherein the medicament comprises at least one compound as active ingredient which is selected from the group consisting of:

(I) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compounds represented by general formula (1):



(1)

[wherein R^1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R^2 represents any group of the following general formulas (A)-(G), wherein

the group represented by the general formula (A) is:



(A)

wherein R^3 represents any group of the following (1)-(6):

(1) a phenoxy group (at least one group selected from the group consisting of a halogen atom, ~~an optionally halogen-substituted C1-6 alkyl group and~~

an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(2) a phenyl C1-6 alkoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(3) NR^4R^5 group, wherein R^4 represents a hydrogen atom or C1-6 alkyl group and R^5 represents a phenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(4) a phenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

(5) a phenoxy C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring); and

(6) a benzofuryl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6

alkoxy group may be substituted on the benzofuran ring);

the group represented by the general formula (B) is:



(B)

wherein R^6 represents phenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (C) is:



(C)

wherein R^7 represents a phenyl C2-10 alkenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or a biphenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (D) is:



(D)

wherein R^8 represents a phenyl C1-6 alkenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);

the group represented by the general formula (E) is:



(E)

(wherein R^8 is as described above); and

the group represented by the general formula (F) is:



(F)

(wherein R^8 is as described above),

the group represented by the general formula (G) is:



(G)

(wherein R^6 is as described above)],

optically active forms thereof and pharmacologically acceptable salts thereof.

25. A kit for tuberculosis treatment, wherein the kit comprises the medicament of claim 24, and at least

one drug (II) selected from the group consisting of primary antituberculous drugs, secondary antituberculous drugs, quinolone antibacterial drugs, macrolide antibacterial drugs, sulfa drugs and anti-HIV drugs, and wherein the kit is used to dose the medicament and the drugs at an interval of 48 hours or more.

26. The kit according to claim 25, wherein the drug of (II) is at least one selected from the group consisting of the primary antituberculous drugs, the secondary antituberculous drugs and the quinolone anti bacterial drugs.

27. The kit according to claim 26, wherein the at least one selected from the primary antituberculous drugs is at least one selected from the group consisting of rifamycin and related anti-bacterial drugs, isoniazid, ethambutol, streptomycin, pyrazinamide and salts thereof, and the secondary antituberculous drugs are at least one selected from the group consisting of enviomycin, kanamycin, capreomycin, cycloserine, thioacetazone, clofazimine and salts thereof, and the at least one selected from the quinolone antibacterial drugs is at least one selected from the group consisting of gatifloxacin, moxifloxacin and hydrate thereof.

28. The kit according to claim 27, wherein the drug of (II) is at least one primary antituberculous drug selected from the group consisting of rifamycin

and related anti-bacterial drugs, isoniazid, ethambutol, streptomycin, pyrazinamide and salts thereof.

29. The kit according to claim 28, wherein the drug of (II) comprises in combination at least one primary antituberculous drug selected from the groups consisting of rifamycin and related antibacterical drugs, isoniazid, ethambutol, streptomycin, pyrazinamide and salt thereof, and at least one quinolone antibacterial drug selected from the group consisting of gatifloxacin, moxifloxacin and hydrate thereof.

30. The kit according to any one of claims 27 to 29, wherein the at least one selected from the rifamycin and related anti-bacterial drugs is at least one selected from the group consisting of rifampicin, rifabutin and rifapentine.